Martinsried, Germany, February 21, 2011. Proteros Biostructures GmbH (“Proteros”) and
Max Planck Institute (“MPI”) of Biochemistry, Martinsried announced today that Dr. Axel
Ullrich has chosen Proteros as the preferred service partner to support kinase drug discovery
research at the Department of Molecular Biology.

Proteros will develop kinase-focused assay systems and provide screening services
employing its proprietary platform for screening to support the validation of novel kinase
targets for drug discovery.

Dr. Axel Ullrich, co-founder of four drug discovery companies and key researcher in the
development of two successfully marketed kinase drugs said that he has chosen Proteros as
preferred partner for his continued drug discovery projects. Dr. Ullrich stated that he has
successfully cooperated with Proteros on several projects during the past few years and is
pleased with Proteros’ performance. Moreover he stated, “Proteros has proven to be a
reliable and flexible partner with expertise in characterizing compound-target interactions and
in the development of biochemical and cellular assay technologies.”

About Proteros:

Proteros is a privately held company that provides services and proprietary technologies to
support integrated drug discovery within life sciences. The company accelerates and
improves protein structure analysis, kinetic and thermodynamic compound-target interaction
studies and structure-guided drug discovery with its expertise, industrialized processes and
unique technologies for crystallography, screening, and fragment-based lead generation.
Proteros currently provides services for more than 80 pharmaceutical and biotechnology
clients in Europe, North America and Japan.

About Dr. Axel Ullrich:

Dr. Ullrich is one of the leading cancer and kinase experts worldwide and among the 10 most
cited scientists over the past 30 years. Dr. Ullrich is co-founder of the companies SUGEN,
Axxima Pharmaceuticals, U3 Pharma and Kinaxo. His research resulted in the development
of anti cancer drugs as Herceptin® and SUTENT®. Dr. Ullrich today is Director of the
Department of Molecular Biology at the Max Planck Institute of Biochemistry in Martinsried.